Fintech PR
Pancreatic Cancer Treatments Poised for Major Advances in 2024
FN Media Group Presents USA News Group News Commentary
VANCOUVER, BC, Feb. 7, 2024 /PRNewswire/ — USA News Group – One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer. As well, the deadly disease showed pancreatic cancer rates rising faster among women, causing increased alarm amongst doctors. Thankfully, 2023 also gave a lot of hope in terms of new treatments for the market that could reach US$36 billion by 2036, such as a potential mRNA vaccine, and other developments from biotech companies to lead into 2024, like Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Incyte Corporation (NASDAQ:INCY), Tango Therapeutics, Inc. (NASDAQ:TNGX), RayzeBio, Inc. (NASDAQ:RYZB) and its buyer Bristol-Myers Squibb Company (NYSE:BMY).
After closing out 2022 with another fast track designation, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) and its flagship asset pelareorep continues to make strides in the battle against pancreatic cancer. This recognition came after pelareorep plus atezolizumab with gemcitabine and nab-paclitaxel achieved an impressive objective response rate (ORR) of 69%. The results were enough to garner the support of the Pancreatic Cancer Action Network (PanCAN), who selected pelareorep to receive the US$5 million Therapeutic Accelerator Award.
“2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy,” said Dr. Matt Coffey, President and CEO of Oncolytics. “To date, we have studied pelareorep in more than 1,100 patients, and it has been shown to be well-tolerated with mild side effects. We believe our cash balance and strong data, supported by our active business development program, position us well for 2024.”
Most recently, Oncolytics added accomplished biopharmaceutical executive Pat Andrews to its Board of Directors. She comes with a track record of success in corporate strategy, first-in-class and first-for-the-company new product commercializations and business development, and a resume that includes 17 years with Pfizer leading a $900-million portfolio at the time, and later serving as CEO of Sumitomo Pharma Oncology (SMP), and as the Chief Commercial Officer for Incyte Corporation (NASDAQ:INCY), where she led the company through the launch of Jakafi, Incyte’s first commercial product.
“I am honored to join the Oncolytics board at this exciting time for the organization as it advances pelareorep toward registrational studies,” said Ms. Andrews. “Promising recent results from the BRACELET-1 and GOBLET studies suggest that pelareorep has the potential to make an important contribution to cancer care, and I look forward to working with my fellow board members in addition to Dr. Coffey and the Executive Team to execute Oncolytics’ clinical and corporate development plans.”
Andrews’s previous employer Incyte Corporation (NASDAQ:INCY) also continues to be active in the pancreatic cancer space itself. Like Oncolytics Biotech, Incyte is also involved with PanCAN in bringing potentially pioneering treatment options to patients.
Now, the market is watching out for the potential future approval of Incyte’s INCA-33890 for pancreatic cancer, which is currently in Phase I. INCA-33890 is a novel PD-1x TGFbR2 bispecific antibody designed to conditionally antagonize TGF signaling in primary immune cells co-expressing PD-1.
Through a licensing deal with Swedish pharmaceutical company Medivir, Tango Therapeutics, Inc. (NASDAQ:TNGX) received FDA clearance on its Investigational New Drug application for TNG348 back in September 2023. Now, in early 2024, Tango has dosed the first patient for the drug in a phase 1/2 clinical study. Tango licensed TNG348 from Medivir back in 2020.
TNG348 is a novel USP1 inhibitor for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers. HRD+ cancers, including BRCA1/2 mutations, represent 5% of pancreatic cancers.
“The preclinical data generated by Tango for TNG348 is promising and dosing the first patient in a clinical study is encouraging for patients with HRD+ cancers,” said Jens Lindberg, CEO of Medivir. “The efforts undertaken by Tango to develop TNG348 into a clinical-staged drug are impressive and we will continue to follow the clinical development of TNG348 with great anticipation.”
Closing out 2023, Bristol-Myers Squibb Company (NYSE:BMY) struck a deal for roughly $4.1 billion to buy RayzeBio, Inc. (NASDAQ:RYZB), with the highlight of the deal being RYZ101, which is being tested in late-stage studies for a rare type of pancreatic cancer. It’s a drug that uses radioactive particles to kill tumor cells.
“[The RayzeBio acquisition] further strengthens our growth opportunities in the back half of the decade and beyond,” said Chris Boerner, newly-appointed CEO of BMY.
“Acquiring RayzeBio’s differentiated actinium-based radiopharmaceutical platform will establish Bristol Myers Squibb’s presence in one of the most promising and fastest-growing new modalities for the treatment of patients with solid tumors – delivering radioactive payloads to cancer cells in a targeted manner,” added Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Drug Development of Bristol Myers Squibb. “In addition, RayzeBio’s platform has the potential to be a significant IND engine, generating several therapeutic candidates in the future by leveraging our global drug development capabilities and infrastructure.”
Article Source: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/
Article Source:
USA News Group
http://USAnewsgroup.com [email protected]
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
This release contains “forward-loking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact Information:
FN Media Group, LLC
Media Contact e-mail:
[email protected]
U.S. Phone: +1(954)345-0611
View original content:https://www.prnewswire.co.uk/news-releases/pancreatic-cancer-treatments-poised-for-major-advances-in-2024-302055604.html
From its first-ever store in Germany to a new shop opened in a local Spanish mall, the bubble tea brand’s expanding support for single-store partners is creating valuable business opportunities in the region while driving its own expansion.
BIRMINGHAM, Sept. 20, 2024 /PRNewswire/ — After making single-store partnerships available earlier this year, premium bubble tea franchise CoCo Bubble Tea is announcing major milestones in Europe and the UK, along with regional supply chain improvements to further assist partners. To help entrepreneurs understand and access everything CoCo offers franchise partners, the brand will attend The National Franchise Exhibition on October 4-5 in Birmingham, UK (Booth T40).
To learn more: https://www.coco-tea.com/Franchise
“CoCo does as much as possible for our franchisee network, and our partners in Europe and the UK have been phenomenal,” commented Kody Wong, Director of Business Development at CoCo Bubble Tea. “Their drive and passion for bubble tea have resulted in a number of ‘firsts’ for the region, and we’ve responded in kind by working hard to further streamline supply chains and manage down costs.”
Distinguished for partner-centric approach
CoCo sets itself apart in the industry by focusing on the long-term success of franchise partners and continuously improving support. In March 2024, CoCo first made single-store franchise partnerships available to individual entrepreneurs in Europe and the UK, while it also expanded region-dedicated supply channels and training programs.
Recently, the brand further augmented supply chain infrastructure in the region to maximize margins for partners. This includes setting up a dedicated regional warehouse to minimize shipping times for materials.
Single-store partners driving growth and localisation
Europe’s bubble tea market is projected to grow at a CAGR of 8% until 2032, and CoCo’s single-store partners are helping the brand to harness this growth. Since CoCo’s move in March, European and UK markets have reached major growth milestones. These include opening new stores in:
- Glasgow
- Rome
- Antwerp
- Valencia
- Granada
- The first-ever CoCo Bubble Tea shop in Germany
For one new store in Spain, upon opening in a local Spanish mall, the shop was met with significant interest from nearby residents, demonstrating the ability of CoCo Bubble Tea shops to seamlessly integrate into European locales. With its extensive menu and R&D capabilities, the brand can easily adapt to any consumer tastes, culture, and community. Furthermore, recent openings in Spain show how the brand’s shops bring value to consumers while also fostering the growth of local economies and businesses.
Why partner with CoCo
Operating with a franchise business model, CoCo Bubble Tea is deeply invested in the entrepreneurs it partners with to open shops. With over 5000 stores worldwide, CoCo combines its high brand recognition with comprehensive support across supply chain, training programs, and other areas to ensure the long-term success of its franchise partners.
For further information, please join CoCo at Booth T40 at The National Franchise Exhibition on October 4-5 in Birmingham, UK (The National Exhibition Centre).
About CoCo Bubble Tea
CoCo Bubble Tea aims to create a diverse and sustainable community for its consumers by providing visually refreshing products. We continue to be one of the fastest-growing companies and are looking for enterprising partners to join the CoCo Bubble Tea franchise networks. Check CoCo Bubble Tea’s official website and start your application now.
For more information, please visit https://www.coco-tea.com/.
Photo – https://mma.prnewswire.com/media/2503742/Press_Release.jpg
View original content:https://www.prnewswire.co.uk/news-releases/uk–european-small-business-owners-take-coco-bubble-tea-to-new-heights-302246373.html
Fintech PR
Fraud Detection & Prevention Market to Reach $252.7 Billion, Globally, by 2032 at 24.3% CAGR: Allied Market Research
The introduction of big data analytics, cloud computing services, and an upsurge in mobile payment drive the growth of the market.
PORTLAND, Ore., Sept. 20, 2024 /PRNewswire/ — Allied Market Research published a report, titled, “Fraud Detection & Prevention Market by Component (Solution and Service), Deployment Mode (On-Premises and Cloud), Organization Size (Large Enterprises and Small and Medium-sized Enterprises) and Industry Vertical (BFSI, IT and Telecom, Retail, Healthcare, Government and Defense, Manufacturing, Transportation and Logistics and Others): Global Opportunity Analysis and Industry Forecast, 2023-2032″. According to the report, the “fraud detection & prevention market” was valued at $29.5 billion in 2022, and is projected to reach $252.7 billion by 2032, growing at a CAGR of 24.3% from 2023 to 2032.
The introduction of big data analytics, cloud computing services, and an upsurge in mobile payment drive the growth of the market. In addition, the rise in the adoption of banking & financial sectors across the globe fuels the growth of the market. Moreover, continuous technological advancements are expected to provide lucrative opportunities for the growth of the market during the forecast period. On the contrary, the high cost of fraud detection and prevention solutions limits the growth of the fraud detection & prevention market.
Request Sample Pages: https://www.alliedmarketresearch.com/request-sample/2142
The solution segment held the highest market share in 2022.
By component, the solution segment dominated the market in 2022, this dominance is driven by the increasing demand for advanced technological solutions that can effectively detect, monitor, and prevent fraudulent activities across various industries such as banking, e-commerce, and insurance. Solutions like AI-based fraud detection, machine learning algorithms, and behavioral analytics have become critical tools in identifying potential fraud in real time and reducing financial losses. However, the service segment is expected to witness the largest CAGR of 28.0%, this growth is driven by the increasing need for specialized services such as consulting, implementation, and maintenance to help organizations effectively integrate and optimize fraud detection solutions.
The BFSI segment held the highest market share in 2022.
By industry vertical, the BFSI segment accounted for the largest share in 2022. This is primarily due to the high frequency and sophistication of fraud targeting financial institutions, making fraud detection and prevention solutions a critical need in the BFSI sector. Financial transactions, online banking, and digital payments are particularly vulnerable to cyberattacks, phishing schemes, and identity theft, driving the sector’s substantial investment in advanced fraud detection technologies. However, the retail segment is expected to witness the largest CAGR of 32.7%. This anticipated growth is driven by several factors. Retailers are increasingly targeted by fraudsters due to the high volume of transactions and the sensitivity of customer data involved. As e-commerce and digital transactions expand, the need for advanced fraud detection and prevention solutions becomes more critical.
Enquiry Before Buying: https://www.alliedmarketresearch.com/purchase-enquiry/2142
Regional Insights: The North America region held the highest market share in 2022.
By region, the fraud detection & prevention market was dominated by North America in 2022. North America, particularly the U.S., has a highly developed financial and technological infrastructure that supports advanced fraud detection solutions. The region’s significant investments in cybersecurity and fraud prevention technologies, combined with a high incidence of cyber threats, drive continuous innovation and adoption of sophisticated fraud management systems.
Buy this Complete Report (415 Pages PDF with Insights, Charts, Tables, and Figures) at:
https://www.alliedmarketresearch.com/fraud-detection-and-prevention-market/purchase-options
Key Industry Developments
- In February 2024, the U.S. Department of the Treasury announced that it has recovered over $375 million as a result of its implementation of an enhanced fraud detection process that utilizes Artificial Intelligence (AI) at the beginning of Fiscal Year 2023.
- In April 2024, Cognizant collaborated with FICO, to launch a cloud-based real-time payment fraud prevention solution powered by FICO Falcon Fraud Manager. The joint offering would leverage both firms’ artificial intelligence (AI) and machine learning (ML) technology to help banks and other payment service providers in North America protect their customers from fraud in the growing world of instant digital payments.
- In September 2022, Deutsche Bank collaborated with Visa, to help prevent online retail fraud. Merchants who process their e-commerce payments via Deutsche Bank can now use “Decision Manager,” an automated fraud detection system from Visa-owned company Cybersource.
AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model):
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access
About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports Insights” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies, and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Int’l: +1-503-894-6022
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
India (Pune): +91-20-66346060
Fax: +1-800-792-5285
[email protected]
Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/fraud-detection–prevention-market-to-reach-252-7-billion-globally-by-2032-at-24-3-cagr-allied-market-research-302253960.html
Fintech PR
KuCoin’s Alicia Kao Shares Insights on How AI is Accelerating Mass Crypto Adoption at TOKEN2049 Singapore
VICTORIA, Seychelles, Sept. 20, 2024 /PRNewswire/ — Alicia Kao, Managing Director at leading global cryptocurrency exchange, KuCoin, shared her vision on how crypto exchanges are the drivers that hold the keys to unlocking mainstream crypto adoption. Speaking at the OKX Main Stage at TOKEN2049 in Singapore on a panel session titled “Exchanges at the Helm: Driving Crypto from Niche to Mainstream,” Alicia shared that “accessing information about blockchain has become significantly easier…at KuCoin, we leverage complex data analysis algorithms using our trading bots to help users trade more efficiently.”
Industry stakeholders from all groups were in attendance for the panel, comprising investors, crypto enthusiasts, and more. The focus was on the crucial role of cryptocurrency exchanges in paving the way for crypto adoption and the eventual integration of digital assets into mainstream financial systems. Alicia and her fellow panelists explored both the challenges and opportunities that lay ahead for the crypto industry.
Alongside Alicia, the panel also featured leaders from leading crypto exchanges such as Ben Zhou, Co-Founder and CEO of Bybit; Gracy Chen, CEO of Bitget; Vivien Lin, Chief Product Officer of BingX; and Sonia Shaw, President of CoinW, and moderated by Michael Casey, Chairman of the Decentralized AI Society.
In addition to the panel discussion, KuCoin cemented its position as a leading centralised exchange (CEX) with a prominent presence on the show floor and activations that showcased the platform’s latest developments. The KuCoin Arcade also drew significant attention, offering an engaging and immersive experience with interactive crypto-themed games and activities.
“As we wrap up another edition of TOKEN2049 in Singapore, I’m once again filled with optimism for the future of the crypto industry. The energy, innovation, and collaboration displayed over the past two days have been immensely inspiring. At KuCoin, we will continue striving to be the driving force in this ever evolving space to build a more inclusive, decentralised, and prosperous financial future” added Alicia as TOKEN2049 concluded.
About KuCoin
Launched in September 2017, KuCoin is a leading cryptocurrency exchange with its operational headquarters in Seychelles. As a user-oriented platform with a focus on inclusiveness and community engagement. It offers over 900 digital assets across Spot trading, Margin trading, P2P Fiat trading, Futures trading, and Staking to its 34 million users in more than 200 countries and regions. KuCoin ranks as one of the top 6 crypto exchanges. KuCoin was acclaimed as “One of the Best Crypto Apps & Exchanges of June 2024” by Forbes Advisor and has been included as one of the top 50 companies in the “2024 Hurun Global Unicorn List”. Learn more at https://www.kucoin.com/.
Logo – https://mma.prnewswire.com/media/2356857/KuCoin_Horizontal_Green_LOGO_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/kucoins-alicia-kao-shares-insights-on-how-ai-is-accelerating-mass-crypto-adoption-at-token2049-singapore-302253906.html
-
Fintech PR7 days agoMedius Wins 2024 ISV Partner of the Year Award in Sweden
-
Fintech PR7 days agoMagic Compass Group Launches New Brand and Prop Trading Business
-
Fintech PR7 days agoATFX Connect Launches NDFs
-
Fintech PR7 days agoBingX Lists AgentLayer on Launchpool, Unlocking New Staking Opportunities
-
Fintech PR6 days agoKuCoin Cares Extends up to 10,000 KCS Humanitarian Aid to Typhoon Yagi Victims in Vietnam
-
Fintech PR5 days agoResponse to possible offer announcement by ABC Technologies Inc. (“ABC Technologies”)
-
Fintech PR6 days agoTIME, Statista Name Three SM companies Among World’s Best Companies
-
Fintech PR7 days agoSeaBubbles Accelerates Sustainable Maritime Mobility with SmartBubble and Strategic Acquisition